16.03
-0.15 (-0.93%)
| Previous Close | 16.18 |
| Open | 16.16 |
| Volume | 726,329 |
| Avg. Volume (3M) | 460,658 |
| Market Cap | 5,715,277,824 |
| Price / Earnings (Forward) | 15.02 |
| Price / Sales | 1.11 |
| Price / Book | 0.910 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2026 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Bausch + Lomb Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.00 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Caspian Capital Lp | 31 Dec 2025 | 1,999,043 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (Citigroup, 31.00%) | Buy |
| Median | 20.00 (24.77%) | |
| Low | 16.00 (Stifel, -0.19%) | Hold |
| Average | 19.00 (18.53%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 17.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Feb 2026 | 20.00 (24.77%) | Buy | 17.99 |
| Barclays | 19 Feb 2026 | 20.00 (24.77%) | Hold | 17.65 |
| Citigroup | 19 Feb 2026 | 21.00 (31.00%) | Buy | 17.65 |
| Stifel | 19 Feb 2026 | 16.00 (-0.19%) | Hold | 17.65 |
| 17 Feb 2026 | 15.00 (-6.43%) | Hold | 17.73 | |
| Wells Fargo | 19 Feb 2026 | 18.00 (12.29%) | Hold | 17.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALFONSO EDUARDO | 15.90 | - | 1,375 | 21,863 |
| COLLIS STEVEN H | 15.90 | - | 1,415 | 22,499 |
| PAULSON JOHN | 15.90 | - | 1,375 | 21,863 |
| ROBERTSON RUSSEL C | 15.90 | - | 1,611 | 25,615 |
| Aggregate Net Quantity | 5,776 | |||
| Aggregate Net Value ($) | 91,838 | |||
| Aggregate Avg. Buy ($) | 15.90 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ALFONSO EDUARDO | Director | 30 Apr 2026 | Acquired (+) | 1,375 | 15.90 | 21,863 |
| COLLIS STEVEN H | Director | 30 Apr 2026 | Acquired (+) | 1,415 | 15.90 | 22,499 |
| PAULSON JOHN | Director | 30 Apr 2026 | Acquired (+) | 1,375 | 15.90 | 21,863 |
| ROBERTSON RUSSEL C | Director | 30 Apr 2026 | Acquired (+) | 1,611 | 15.90 | 25,615 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |